Tag: tranche

Dubai and New York, June 2, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), today announces the successful closing of a USD 1.4 billion dual-tranche senior unsecured notes offering (the “Offering”) by its subsidiary VEON Midco B.V. (the “Issuer”). The Offering refinances substantially all of VEON’s debt maturing in 2027 ahead of schedule and reflects sustained confidence in VEON’s digital operator transformation and AI1440 strategy.

Please see below information about transactions made under the second tranche of the 2026 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2025.

On 5 February 2025, Pandora announced a new share buyback programme, cf. Company announcement no. 923. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
                                                                                                                                                      
The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes.

Please see below information about transactions made under the third tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Company Announcement

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed the first tranche of its previously announced private placement offering (the “Offering”). The first tranche of the Offering consisted of the issuance of 2,900,000 units of the Company (each, a “Unit”), at a price of $0.021 per Unit, for total gross proceeds to Revive of $60,900. Furthermore, the Company announces that it has settled an amount of $67,400 owing pursuant to an arm’s length note through the issuance of 3,209,523 Units, at a price of $0.021 per Unit, being the same issue price and security offered pursuant to the Offering.